ABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
